Back to Search Start Over

Lipophilic conformationally constrained spiro carbocyclic 2,6-diketopiperazine-1-acetohydroxamic acid analogues as trypanocidal and leishmanicidal agents: An extended SAR study

Authors :
John M. Kelly
Andrew Tsotinis
Antonia Efstathiou
Despina Smirlis
Martin C. Taylor
G. Fytas
Grigoris Zoidis
Alexandra Tsatsaroni
Source :
Chemical Biology & Drug Design. 91:408-421
Publication Year :
2017
Publisher :
Wiley, 2017.

Abstract

We have previously described a number of lipophilic conformationally constrained spiro carbocyclic 2,6-diketopiperazine (2,6-DKP)-1-acetohydroxamic acids as potent anti-trypanosomal agents. In this report, we extend the SAR analysis in this class of compounds with respect to in vitro growth inhibition of Trypanosoma and Leishmania parasites. Introduction of bulky hydrophobic substituents at the vicinal position of the basic nitrogen atom in the spiro carbocyclic 2,6-DKP ring system can provide analogues which are potently active against bloodstream-form T. brucei and exhibit significant activities towards T. cruzi epimastogotes and L. infantum promastogotes and intracellular amastigotes. In particular, compounds possessing a benzyl or 4-chlorobenzyl substituent were found to be the most active growth inhibitors, with activities in the low nanomolar and low micromolar ranges for T. brucei and L. infantum, respectively. The benzyl substituted (S)-enantiomer was the most potent derivative against T. brucei (IC50 =6.8 nM), T. cruzi (IC50 =0.21 μΜ) and L. infantum promastigotes (IC50 =2.67 μM) and intracellular amastigotes (IC50 =2.60 μM). Moreover, the (R)-chiral benzyl substituted derivative and its racemic counterpart displayed significant activities against L. donovani. Importantly, the active compounds show high selectivity in comparison with two mammalian cell lines. This article is protected by copyright. All rights reserved.

Details

ISSN :
17470277
Volume :
91
Database :
OpenAIRE
Journal :
Chemical Biology & Drug Design
Accession number :
edsair.doi.dedup.....e3ee73cc8f14c17d4d3a95e2308d7f81